DNA vaccines for biodefense

Expert Review of Vaccines

Volumn 8, Issue 12, 2009, Pages 1739-1754

  Dupuy, Lesley C ^a   Schmaljohn, Connie S ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Alphavirus; Anthrax; Bacillus anthracis; Biodefense; DNA vaccine; Ebola virus; Electroporation; Gene gun; Marburg virus; Monkeypox virus; Poxvirus; Smallpox; Vaccinia virus; Variola virus; Venezuelan equine encephalitis virus

Indexed keywords

1,2 DIOLEOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; 1,2 DIPHYTANOYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; [[N(2 HYDROXYETHYL)N,N DIMETHYL 2,3 BIS(TETRADECYLOXY) 1 PROPANAMINIUM BROMIDE; [[N(3 AMINOPROPYL)N,N DIMETHYL 2,3 BIS(CIS 9 TETRADECENYLOXY) 1 PROPANAMINIUM BROMIDE]]; ADENOVIRUS VECTOR; ANTHRAX VACCINE; DNA VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGIC AGENT; INACTIVATED VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VAXFECTIN;

ALPHA VIRUS; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; DRUG DELIVERY SYSTEM; EASTERN EQUINE ENCEPHALOMYELITIS VIRUS; EBOLA VIRUS; ECZEMA; ELECTROPORATION; ENCEPHALOMYELITIS; FILOVIRUS; GENE GUN IMMUNIZATION; HUMAN; IMMUNITY; IMMUNOGENICITY; MARBURG VIRUS; MYOCARDITIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SMALLPOX; SMALLPOX VIRUS; VACCINIA; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; WESTERN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ADULT; ANIMALS; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; BIOLISTICS; BIOTERRORISM; EBOLAVIRUS; ELECTROPORATION; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; RABBITS; SMALLPOX; VACCINES, DNA; VARIOLA VIRUS; VIRAL VACCINES;

EID: 73849111645     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.132     Document Type: Review

References (76)

1. Hartikka J, Bozoukova V, Ferrari M et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19(15-16), 1911-1923 (2001).
2. Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particlemediated DNA vaccines for infectious diseases. Methods 40(1), 86-97 (2006).
3. Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol. Ther. 7(11), 1647-1664 (2007). • Comprehensive review of DNA vaccine delivery by electroporation.
4. Milne JC, Blanke SR, Hanna PC, Collier RJ. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol. 15(4), 661-666 (1995).
5. Duesbery NS, Webb CP, Leppla SH et al. Proteolytic inactivation of MAP-kinasekinase by anthrax lethal factor. Science 280(5364), 734-737 (1998).
6. Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl Acad. Sci. USA 79(10), 3162-3166 (1982).
7. Ivins BE, Welkos SL. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect. Immun. 54(2), 537-542 (1986).
8. Welkos S, Little S, Friedlander A et al. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147(Pt 6), 1677-1685 (2001).
9. Welkos SL. Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb. Pathog. 10(3), 183-198 (1991).
10. Perkins SD, Flick-Smith HC, Garmory HS, Essex-Lopresti AE, Stevenson FK, Phillpotts RJ. Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax. Genet. Vaccines Ther. 3(1), 3 (2005).
11. Pitt ML, Little SF, Ivins BE et al. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19(32), 4768-4773 (2001). • Description of an animal model that correlates with human protective immunity for anthrax.
12. Welkos SL, Vietri NJ, Gibbs PH. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb. Pathog. 14(5), 381-388 (1993).
13. Welkos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun. 51(3), 795-800 (1986).
14. Welkos SL, Friedlander AM. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog. 4(1), 53-69 (1988).
15. Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5(2), 127-139 (1988).
16. Flick-Smith HC, Waters EL, Walker NJ et al. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog. 38(1), 33-40 (2005).
17. Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17(4), 340-344 (1999). • First demonstration of DNA vaccine efficacy against anthrax toxin challenge.
18. Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Mol. Ther. 8(3), 392-399 (2003).
19. Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine 21(25-26), 4071-4080 (2003). • Demonstration of protective efficacy in animals with a combination DNA vaccine for four biodefense pathogens, protection of nonhuman primates from Marburg virus challenge, and protection of mice from aerosol challenge with Venezuelan equine encephalitis virus.
20. Luxembourg A, Hannaman D, Nolan E et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 26(40), 5216-5222 (2008).
21. Hahn UK, Alex M, Czerny CP, Bohm R, Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int. J. Med. Microbiol. 294(1), 35-44 (2004).
22. Hahn UK, Aichler M, Boehm R, Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine 24(21), 4595-4597 (2006).
23. Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int. J. Pharm. 331(2), 228-232 (2007).
24. Midha S, Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Eur. J. Immunol. 39(1), 159-177 (2009).
25. Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69(7), 4509-4515 (2001).
26. Hermanson G, Whitlow V, Parker S et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibodymediated protection against aerosolized anthrax spores. Proc. Natl Acad. Sci. USA 101(37), 13601-13606 (2004).
27. Vilalta A, Mahajan RK, Hartikka J et al. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum. Gene Ther. 16(10), 1151-1156 (2005).
28. Keitel WA, Treanor JJ, El Sahly HM et al. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum. Vaccin. 5(8), 536-544 (2009). • First study of anthrax DNA vaccine in humans.
29. Hahn UK, Boehm R, Beyer W. DNA vaccination against anthrax in mice - combination of anti-spore and anti-toxin components. Vaccine 24(21), 4569-4571 (2006).
30. McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax. Mol. Ther. 15(1), 203-210 (2007).
31. Leroy EM, Epelboin A, Mondonge V et al. Human ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. (2009) (Epub ahead of print).
32. Towner JS, Amman BR, Sealy TK et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. 5(7), e1000536 (2009).
33. Alibek K, Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World Told. Dell Publishing, NY, USA (1999).
34. Towner JS, Sealy TK, Khristova ML et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4(11), e1000212 (2008).
35. Feldmann H, Geisbert T, Jahrling P et al. Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. Fauquet C, Mayo M, Maniloff J, Desselberger U, Ball L (Eds). Elsevier/ Academic Press, CA, USA (2005).
36. Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine 25(11), 1923-1934 (2007).
37. Volchkov VE, Volchkova VA, Muhlberger E et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291(5510), 1965-1969 (2001).
38. Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl Acad. Sci. USA 95(10), 5762-5767 (1998).
39. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 179(Suppl. 1), S248-S258 (1999).
40. Warfield KL, Bradfute SB, Wells J et al. Development and characterization of a mouse model for marburg hemorrhagic fever. J. Virol. 83(13), 6404-6415 (2009).
41. Vanderzanden L, Bray M, Fuller D et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology 246(1), 134-144 (1998).
42. Xu L, Sanchez A, Yang Z et al. Immunization for Ebola virus infection. Nat. Med. 4(1), 37-42 (1998).
43. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408(6812), 605-609 (2000).
44. Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol. 13(11), 1267-1277 (2006). • First test of a DNA vaccine for Ebola virus in humans.
45. Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424(6949), 681-684 (2003).
46. Richardson JS, Yao MK, Tran KN et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS ONE 4(4), e5308 (2009).
47. Geisbert TW, Geisbert JB, Leung A et al. Single injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus. J. Virol. 83(14), 7296-7304 (2009).
48. Geisbert TW, Daddario-Dicaprio KM, Lewis MG et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog. 4(11), e1000225 (2008).
49. Swenson DL, Wang D, Luo M et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol. 15(3), 460-467 (2008).
50. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77(1), 799-803 (2003).
51. Hevey M, Negley D, Van der Zanden L et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20(3-4), 586-593 (2001).
52. Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254(1), 71-80 (1999).
53. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266(2), 329-339 (2000).
54. Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 306(1), 181-195 (2003).
55. Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine 25(10), 1814-1823 (2007). • First demonstration of protective efficacy of a DNA vaccine against poxvirus disease in nonhuman primates.
56. Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine 22(25-26), 3358-3366 (2004).
57. Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology 355(2), 164-174 (2006).
58. Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine 26(27-28), 3507-3515 (2008).
59. Shinoda K, Wyatt LS, Irvine KR, Moss B. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol. J. 6, 28 (2009).
60. Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology 368(2), 331-341 (2007).
61. Hooper JW, Thompson E, Wilhelmsen C et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 78(9), 4433-4443 (2004).
62. Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine 24(21), 4461-4470 (2006).
63. Heraud JM, Edghill-Smith Y, Ayala V et al. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177(4), 2552-2564 (2006).
64. Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology 371(1), 98-107 (2008).
65. Golden JW, Hooper JW. Heterogeneity in the A33 protein impacts the crossprotective efficacy of a candidate smallpox DNA vaccine. Virology 377(1), 19-29 (2008).
66. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan equine encephalitis virus. Vaccine 18(7-8), 588-596 (1999).
67. Nagata LP, Hu WG, Masri SA et al. Efficacy of DNA vaccination against western equine encephalitis virus infection. Vaccine 23(17-18), 2280-2283 (2005).
68. Dupuy LC, Locher CP, Paidhungat M et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine 27(31), 4152-4160 (2009).
69. Perkins SD, O'Brien LM, Phillpotts RJ. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Vaccine 24(17), 3440-3445 (2006).
70. Zanin MP, Webster DE, Wesselingh SL. A DNA prime, orally delivered protein boost vaccination strategy against viral encephalitis. J. Neurovirol. 13(3), 284-289 (2007).
71. Dupuy LC, Richards M, Ellefsen B, Hannaman D, Livingston B, Schmaljohn SC. Improved potency of codon-optimized encephalitic alphavirus DNA vaccines delivered by electroporation. Presented at: 7th Annual ASM Biodefense and Emerging Diseases Research Meeting. Baltimore, MD, USA, 22-25 February 2009.
72. Williamson ED, Beedham RJ, Bennett AM, Perkins SD, Miller J, Baillie LW. Presentation of protective antigen to the mouse immune system: immune sequelae. J. Appl. Microbiol. 87(2), 315-317 (1999).
73. Williamson ED, Bennett AM, Perkins SD, Beedham RJ, Miller J, Baillie LW. Coimmunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine 20(23-24), 2933-2941 (2002).
74. Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine 22(13-14), 1604-1608 (2004).
75. Cui Z, Sloat BR. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. Int. J. Pharm. 317(2), 187-191 (2006).
76. Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for ebola virus in guinea pigs. Virus Res. 92(2), 187-193 (2003).